What's new with phentolamine mesylate: a reversal agent for local anaesthesia?

SAAD digest Pub Date : 2011-01-01
John A Yagiela
{"title":"What's new with phentolamine mesylate: a reversal agent for local anaesthesia?","authors":"John A Yagiela","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Phentolamine mesylate (OraVerse), a nonselective a-adrenergic blocking drug, is the first therapeutic agent marketed for the reversal of soft-tissue anaesthesia and the associated functional deficits resulting from an intraoral submucosal injection of a local anaesthetic containing a vasoconstrictor. In clinical trials, phentolamine injected in doses of 0.2 to 0.8 mg (0.5 to 2 cartridges), as determined by patient age and volume of local anaesthetic administered, significantly hastened the return of normal soft-tissue sensation in adults and children 6 years of age and older. Median lip recovery times were reduced by 75 to 85 minutes. Functional deficits, such as drooling and difficulty in drinking, smiling, or talking--and subjects' perception of altered function or appearance--were consistently resolved by the time sensation to touch had returned to normal. Adverse effects of phentolamine injected in approved doses for reversal of local anaesthesia in patients ranging in age from 4 to 92 years were similar in incidence to those of sham injections, and no serious adverse events caused by such use were reported. The clinical use of phentolamine is viewed favorably by dentists who have administered the drug and by patients who have received it. Optimal use may require some modifications of the technique described in the package insert; cost of the agent may be influencing its widespread adoption into clinical practice. Phentolamine mesylate, in the form of OraVerse (Novalar Pharmaceuticals, San Diego, USA) represents a new therapeutic class of drugs in dentistry intended to reverse soft-tissue anaesthesia after nonsurgical dental procedures (e.g., restorative or deep scaling/root planing procedures). As shown in Figure 1, OraVerse is manufactured in 1.7 mL dental cartridges, each of which contains 0.4 mg active drug. This review describes the development of phentolamine as a dental drug, its pharmacologic characteristics, and how it may be used in clinical practice to improve patient care.</p>","PeriodicalId":21571,"journal":{"name":"SAAD digest","volume":"27 ","pages":"3-7"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAAD digest","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Phentolamine mesylate (OraVerse), a nonselective a-adrenergic blocking drug, is the first therapeutic agent marketed for the reversal of soft-tissue anaesthesia and the associated functional deficits resulting from an intraoral submucosal injection of a local anaesthetic containing a vasoconstrictor. In clinical trials, phentolamine injected in doses of 0.2 to 0.8 mg (0.5 to 2 cartridges), as determined by patient age and volume of local anaesthetic administered, significantly hastened the return of normal soft-tissue sensation in adults and children 6 years of age and older. Median lip recovery times were reduced by 75 to 85 minutes. Functional deficits, such as drooling and difficulty in drinking, smiling, or talking--and subjects' perception of altered function or appearance--were consistently resolved by the time sensation to touch had returned to normal. Adverse effects of phentolamine injected in approved doses for reversal of local anaesthesia in patients ranging in age from 4 to 92 years were similar in incidence to those of sham injections, and no serious adverse events caused by such use were reported. The clinical use of phentolamine is viewed favorably by dentists who have administered the drug and by patients who have received it. Optimal use may require some modifications of the technique described in the package insert; cost of the agent may be influencing its widespread adoption into clinical practice. Phentolamine mesylate, in the form of OraVerse (Novalar Pharmaceuticals, San Diego, USA) represents a new therapeutic class of drugs in dentistry intended to reverse soft-tissue anaesthesia after nonsurgical dental procedures (e.g., restorative or deep scaling/root planing procedures). As shown in Figure 1, OraVerse is manufactured in 1.7 mL dental cartridges, each of which contains 0.4 mg active drug. This review describes the development of phentolamine as a dental drug, its pharmacologic characteristics, and how it may be used in clinical practice to improve patient care.

甲磺酸酚妥拉明:局部麻醉的逆转剂有什么新发现?
甲磺酸酚妥拉明(OraVerse)是一种非选择性的a-肾上腺素能阻断药物,是市场上第一种用于软组织麻醉逆转和口腔黏膜下注射含有血管收缩剂的局部麻醉剂导致的相关功能缺陷的治疗药物。在临床试验中,根据患者年龄和局部麻醉剂量的不同,注射剂量为0.2至0.8 mg(0.5至2盒)的酚妥拉明可显著加速成人和6岁及以上儿童正常软组织感觉的恢复。中位唇部恢复时间缩短了75 ~ 85分钟。功能性缺陷,如流口水、饮酒困难、微笑或说话困难,以及受试者对功能或外观改变的感知,在触觉恢复正常的时间内都得到了一致的解决。4岁至92岁的患者中,以批准剂量注射酚妥拉明逆转局部麻醉的不良反应发生率与假注射相似,且未报告因使用此类药物引起的严重不良事件。使用过酚妥拉明的牙医和使用过它的病人都对它的临床应用持赞成态度。最佳使用可能需要对包装说明书中描述的技术进行一些修改;药物的成本可能会影响其在临床实践中的广泛采用。甲磺酸酚托拉明,OraVerse (Novalar Pharmaceuticals, San Diego, USA)的形式,代表了一种新的牙科治疗类药物,旨在逆转非手术牙科手术后的软组织麻醉(例如,恢复性或深度洗牙/牙根刨平手术)。如图1所示,OraVerse是用1.7 mL牙科药盒制造的,每个药盒含有0.4 mg活性药物。本文综述了酚妥拉明作为一种牙科药物的发展,其药理学特性,以及如何在临床实践中使用它来改善病人的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书